The COVID-19 pandemic, initiated by the emergence of SARS-CoV-2 in late 2019, has profoundly impacted global health, with over 704 million infections and seven million deaths. This crisis has not only overwhelmed healthcare systems but also significantly disrupted global economies. The virus’s adaptability, particularly in its transmission, has posed ongoing challenges. In response, interdisciplinary efforts have led to significant advancements in vaccine development, drug discovery, and public health strategies. Computational drug discovery has become pivotal, utilizing in silico techniques to screen existing drugs and identify potential inhibitors targeting viral proteins like the spike (S) and other non-structural proteins. These approaches, including molecular docking and dynamic simulations, have expedited drug discovery by allowing rapid screening of chemical libraries. Additionally, mRNA vaccines have demonstrated high efficacy and rapid production capabilities, marking a significant advancement in vaccine technology. The integration of computational methods with extensive drug libraries and high-performance computing resources has accelerated both drug and vaccine development, highlighting the critical role of global collaboration in managing and mitigating the pandemic’s impact.